Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-07: Form 8-K; Period of report 2019-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-08-23: Form 8-K; Period of report 2019-08-22; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 2.03.
- 2019-08-13: Form 8-K; Period of report 2019-08-07; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2019-08-01: Form 8-K; Period of report 2019-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-07 | 8-K | 2019-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2019, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2019. | d825747d8k.htm |
| 2019-08-23 | 8-K | 2019-08-22 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 2.03 On August 23, 2019, Clovis Oncology, Inc. (the “Company”) completed the sale of $13,000,000 million aggregate principal amount of its 4.50% Convertible Senior Notes due 2024 (the “Additional Notes”). 3.02 The information with respect to the Notes and the Indenture set forth in Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 On August 22, 2019, the Company issued a press release announcing the exercise by the initial purchasers’ of their option to purchase the Additional Notes. | d753562d8k.htm |
| 2019-08-13 | 8-K | 2019-08-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On August 13, 2019, Clovis Oncology, Inc. (the “Company”) consummated the offering of $250 million aggregate principal amount of its 4.50% Convertible Senior Notes due 2024 (the “Notes”). 2.03 The information with respect to the Notes and the Indenture and set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information with respect to the Notes and the Indenture and set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 The Company used approximately $171.8 million of the net proceeds from the sale of the Notes to repurchase $190.3 aggregate principal amount of its outstanding 2021 Notes in privately negotiated transactions. | d770430d8k.htm |
| 2019-08-01 | 8-K | 2019-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2019, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2019. | a52024769.htm |
| 2019-07-01 | 8-K | 2019-07-01 | 3.02 Unregistered Sales of Equity Securities | 3.02 On July 1, 2019, Clovis Oncology, Inc. (the “Company”) issued 1,482,058 shares of common stock of the Company (the “Settlement Shares”) to Antipodean Domestic Partners, L.P. (“Antipodean”) pursuant to the previously disclosed Settlement Agreement with Antipodean. | d774904d8k.htm |
| 2019-06-17 | 8-K | 2019-06-14 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 The information set forth in Item 8.01 below is incorporated by reference into this Item 3.02. 8.01 On June 14, 2019, the Company and Antipodean Domestic Partners, L.P. (“Antipodean”) entered into an agreement (the “Settlement Agreement”) to settle the lawsuit filed by Antipodean against the Company, certain of its officers and directors and underwriters currently pending in New York state court. | d724885d8k.htm |
| 2019-06-11 | 8-K/A | 2019-06-05 | 5.07 Submission of Matters to a Vote of Security Holders | d765959d8ka.htm | |
| 2019-06-06 | 8-K | 2019-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 5, 2019, Dr. M. James Barrett informed Clovis Oncology, Inc. (the “Company”) that he would resign from the Board of Directors of the Company (the “Board”) effective immediately. 5.03 On April 11, 2019, the Board approved an amendment, subject to stockholder approval, to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000. 5.07 The Annual Meeting of Stockholders of the Company was held on June 6, 2019. | d568255d8k.htm |
| 2019-05-07 | 8-K | 2019-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2019, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2019. | a51980538.htm |
| 2019-05-02 | 8-K | 2019-05-01 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On May 1, 2019, Clovis Oncology, Inc., a Delaware corporation (the “Company”), and certain subsidiaries of the Company, as Guarantors, entered into a Financing Agreement (the “Financing Agreement”) with certain affiliates of TPG Sixth Street Partners, LLC as lenders (collectively, the “Lenders”) and as the administrative agent. 2.03 (a) The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the Financing Agreement and the Security Agreement is hereby incorporated by reference. | d723951d8k.htm |
| 2019-04-12 | 8-K | 2019-04-12 | 8.01 Other Events | 8.01 Clovis Oncology, Inc. (“Clovis”) is discontinuing its sponsored Phase 2 open-label monotherapy clinical trial evaluating rucaparib in recurrent, metastatic bladder cancer (CO-338-085 (“ATLAS”)). | d719637d8k.htm |
| 2019-03-14 | 8-K | 2019-03-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) On March 14, 2019, Clovis Oncology, Inc. (the “Company”) entered into amendments to the employment agreements with each of Patrick Mahaffy, Daniel Muehl, Gillian Ivers-Read and Paul Gross, pursuant to which each agreed, without additional consideration, to the deletion of the provisions which would have entitled him or her to receive a gross-up payment in the event excise taxes would be imposed on any “parachute payments” under Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended (a “280G Gross-Up”). | d719711d8k.htm |
| 2019-02-26 | 8-K | 2019-02-26 | 2.02 Results of Operations and Financial Condition | 2.02 On February 26, 2019, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2018. | a51946133.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2019, Clovis Oncology, Inc. (the “Company”) issued a press release announcing certain unaudited preliminary financial results for the quarter and fiscal year ended December 31, 2018. | d685621d8k.htm |